- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Medicine
Volume 2013 (2013), Article ID 712383, 3 pages
Ventricular Tachycardia Induced by Weight Loss Pills
Department of Cardiology, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark
Received 20 December 2012; Accepted 22 February 2013
Academic Editor: David Brown
Copyright © 2013 Manan Pareek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. M. John, U. B. Tedrow, B. A. Koplan et al., “Ventricular arrhythmias and sudden cardiac death,” The Lancet, vol. 380, no. 9852, pp. 1520–1529, 2012.
- E. N. Prystowsky, B. J. Padanilam, S. Joshi, and R. I. Fogel, “Ventricular arrhythmias in the absence of structural heart disease,” Journal of the American College of Cardiology, vol. 59, no. 20, pp. 1733–1744, 2012.
- D. P. Zipes, A. J. Camm, M. Borggrefe et al., “European Heart Rhythm Association; Heart Rhythm Society; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),” Journal of the American College of Cardiology, vol. 48, pp. e247–e346, 2006.
- Dietary Supplement Fact Sheet, “Ephedra and Ephedrine Alkaloids for Weight Loss and Athletic Performance,” Office of Dietary Supplements (ODS), 2004, http://ods.od.nih.gov/factsheets/EphedraandEphedrine-HealthProfessional/.
- C. A. Haller and N. L. Benowitz, “Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids,” New England Journal of Medicine, vol. 343, no. 25, pp. 1833–1838, 2000.
- N. L. Benowitz, “Clinical pharmacology of caffeine,” Annual Review of Medicine, vol. 41, pp. 277–288, 1990.
- D. Robertson, J. C. Froelich, R. K. Carr, et al., “Effects of caffeine on plasma renin activity, catecholamines and blood pressure,” New England Journal of Medicine, vol. 298, no. 4, pp. 181–186, 1978.
- P. G. Shekelle, M. L. Hardy, S. C. Morton et al., “Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis,” Journal of the American Medical Association, vol. 289, no. 12, pp. 1537–1545, 2003.
- “FDA Acts to Remove Ephedra-Containing Dietary Supplements From Market,” U.S. Food and Drug Administration, 2004, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108379.htm.